156 related articles for article (PubMed ID: 20698843)
21. Expression of CD164 on Malignant T cells in Sézary Syndrome.
Guenova E; Ignatova D; Chang YT; Contassot E; Mehra T; Saulite I; Navarini AA; Mitev V; Dummer R; Kazakov DV; French LE; Hoetzenecker W; Cozzio A
Acta Derm Venereol; 2016 May; 96(4):464-7. PubMed ID: 26524186
[TBL] [Abstract][Full Text] [Related]
22. Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses.
Harmon CB; Witzig TE; Katzmann JA; Pittelkow MR
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):404-10. PubMed ID: 8784277
[TBL] [Abstract][Full Text] [Related]
23. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
Yoo EK; Cassin M; Lessin SR; Rook AH
J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
[TBL] [Abstract][Full Text] [Related]
24. Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma.
Fivenson DP; Hanson CA; Nickoloff BJ
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):717-23. PubMed ID: 7929915
[TBL] [Abstract][Full Text] [Related]
25. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
[TBL] [Abstract][Full Text] [Related]
26. Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma.
Hahtola S; Tuomela S; Elo L; Häkkinen T; Karenko L; Nedoszytko B; Heikkilä H; Saarialho-Kere U; Roszkiewicz J; Aittokallio T; Lahesmaa R; Ranki A
Clin Cancer Res; 2006 Aug; 12(16):4812-21. PubMed ID: 16914566
[TBL] [Abstract][Full Text] [Related]
27. TIGIT and Helios Are Highly Expressed on CD4
Jariwala N; Benoit B; Kossenkov AV; Oetjen LK; Whelan TM; Cornejo CM; Takeshita J; Kim BS; Showe LC; Wysocka M; Rook AH
J Invest Dermatol; 2017 Jan; 137(1):257-260. PubMed ID: 27592800
[No Abstract] [Full Text] [Related]
28. CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sézary syndrome.
Rappl G; Muche JM; Abken H; Sterry W; Tilgen W; Ugurel S; Reinhold U
J Am Acad Dermatol; 2001 Mar; 44(3):456-61. PubMed ID: 11209115
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma.
Weng WK; Armstrong R; Arai S; Desmarais C; Hoppe R; Kim YH
Sci Transl Med; 2013 Dec; 5(214):214ra171. PubMed ID: 24307695
[TBL] [Abstract][Full Text] [Related]
30. Significance of circulating T-cell clones in Sezary syndrome.
Ortonne N; Huet D; Gaudez C; Marie-Cardine A; Schiavon V; Bagot M; Musette P; Bensussan A
Blood; 2006 May; 107(10):4030-8. PubMed ID: 16418328
[TBL] [Abstract][Full Text] [Related]
31. Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of Sézary syndrome.
Nagler AR; Samimi S; Schaffer A; Vittorio CC; Kim EJ; Rook AH
J Am Acad Dermatol; 2012 Mar; 66(3):503-8. PubMed ID: 22005074
[TBL] [Abstract][Full Text] [Related]
32. Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma.
Bagot M; Echchakir H; Mami-Chouaib F; Delfau-Larue MH; Charue D; Bernheim A; Chouaib S; Boumsell L; Bensussan A
Blood; 1998 Jun; 91(11):4331-41. PubMed ID: 9596682
[TBL] [Abstract][Full Text] [Related]
33. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values.
Wood GS; Hong SR; Sasaki DT; Abel EA; Hoppe RT; Warnke RA; Morhenn VB
J Am Acad Dermatol; 1990 Apr; 22(4):602-7. PubMed ID: 1690762
[TBL] [Abstract][Full Text] [Related]
34. Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome.
Krejsgaard T; Gjerdrum LM; Ralfkiaer E; Lauenborg B; Eriksen KW; Mathiesen AM; Bovin LF; Gniadecki R; Geisler C; Ryder LP; Zhang Q; Wasik MA; Odum N; Woetmann A
Leukemia; 2008 Dec; 22(12):2230-9. PubMed ID: 18769452
[TBL] [Abstract][Full Text] [Related]
35. Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome.
Rasmussen TA; McMahon J; Chang JJ; Symons J; Roche M; Dantanarayana A; Okoye A; Hiener B; Palmer S; Lee WS; Kent SJ; Van Der Weyden C; Prince HM; Cameron PU; Lewin SR
AIDS; 2017 Aug; 31(13):1839-1845. PubMed ID: 28514279
[TBL] [Abstract][Full Text] [Related]
36. Novel and highly recurrent chromosomal alterations in Sézary syndrome.
Vermeer MH; van Doorn R; Dijkman R; Mao X; Whittaker S; van Voorst Vader PC; Gerritsen MJ; Geerts ML; Gellrich S; Söderberg O; Leuchowius KJ; Landegren U; Out-Luiting JJ; Knijnenburg J; Ijszenga M; Szuhai K; Willemze R; Tensen CP
Cancer Res; 2008 Apr; 68(8):2689-98. PubMed ID: 18413736
[TBL] [Abstract][Full Text] [Related]
37. Aneuploid malignant T cells from a patient with Sézary syndrome can be visualized by in situ hybridization.
Hindkjaer J; Brandt CA; Kaltoft K
Arch Dermatol; 1993 Sep; 129(9):1141-5. PubMed ID: 8363397
[TBL] [Abstract][Full Text] [Related]
38. The clonal nature of circulating Sezary cells.
Weinberg JM; Jaworsky C; Benoit BM; Telegan B; Rook AH; Lessin SR
Blood; 1995 Dec; 86(11):4257-62. PubMed ID: 7492785
[TBL] [Abstract][Full Text] [Related]
39. Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients.
Bensussan A; Remtoula N; Sivori S; Bagot M; Moretta A; Marie-Cardine A
J Invest Dermatol; 2011 Apr; 131(4):969-76. PubMed ID: 21191411
[TBL] [Abstract][Full Text] [Related]
40. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).
Cirée A; Michel L; Camilleri-Bröet S; Jean Louis F; Oster M; Flageul B; Senet P; Fossiez F; Fridman WH; Bachelez H; Tartour E
Int J Cancer; 2004 Oct; 112(1):113-20. PubMed ID: 15305382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
